Albert Hofmann was not chasing visions. He was a pharmaceutical chemist at Sandoz Laboratories in Basel, working through a systematic series of ergot derivatives in search of something useful for the cardiovascular system. LSD-25 — the 25th compound in that series — showed nothing interesting in 1938. He shelved it. Five years later, something he could only describe as intuition pulled him back to it. On April 16, 1943, he accidentally absorbed a trace amount through his skin. Three days later, on April 19 — now marked in certain circles as Bicycle Day — he swallowed 250 micrograms deliberately and rode home through a Basel that had ceased to behave like Basel.

That date matters. Not because it is a countercultural anniversary. Because it marks the moment a twentieth-century pharmaceutical laboratory, operating under fluorescent lights with rigorous methodology, produced something that every mystical tradition in history had described — and none of them had been able to replicate on demand.

Hofmann lived to 102. He spent his remaining decades arguing that LSD, handled with care and in appropriate context, was one of the most valuable tools humanity possessed for understanding the nature of mind. He was not a counterculture figure. He was a rigorous chemist who could not explain what he had found.

The decade after 1943 saw serious scientific engagement. Sandoz distributed LSD freely to researchers worldwide under the name Delysid. Psychiatrists used it in therapy sessions. Then the CIA ran MKULTra — a program that explored LSD for coercive interrogation and mind control, produced almost nothing useful, caused significant harm, and cast a shadow over governmental attitudes toward psychedelics that has not fully lifted. By the 1960s, the compound had escaped the laboratory entirely. By 1970, the United States had classified it Schedule I — no accepted medical use, high abuse potential. Research stopped. It would not meaningfully restart for more than thirty years.

That suppression was not scientifically motivated. It was politically motivated. That distinction has consequences.

Alexander Shulgin held a DEA Schedule I research license — a distinction so rare it was essentially singular. He had a background at Dow Chemical. He had academic credibility. And he spent decades in a weathered laboratory in the hills of Lafayette, California, synthesizing hundreds of novel psychoactive compounds, testing them on himself and a small group of trusted collaborators, and documenting what happened with the precision of a scientist and the honesty of someone who understood exactly what he was risking.

His two books — PIHKAL (Phenethylamines I Have Known and Loved, 1991) and TIHKAL (Tryptamines I Have Known and Loved, 1997), both co-authored with his wife Ann — remain extraordinary objects. Part autobiography. Part love story. Part rigorous chemistry manual with synthesis routes, dosing protocols, and first-person phenomenological reports. The DEA raided his lab in 1994, fined him, and revoked his license. The books were already in the world.

Shulgin's most consequential act was not synthesis. It was introduction. MDMA had been first made by Merck in 1912 and essentially forgotten. Shulgin resynthesized it in the late 1970s and introduced it to the psychiatrist Leo Zeff, who used it in therapeutic sessions and trained hundreds of other therapists in its application before the DEA scheduled it in 1985. That scheduling halted clinical work on a compound that was, by every account from practicing therapists, doing something remarkable for patients who had not responded to anything else.

His philosophy was coherent: altered states of consciousness are data, not pathology. Synthesizing new compounds to map that territory is as valid as building telescopes. Whether you accept this or find it reckless, it is a position — and it is the position that serious therapeutic research has quietly been vindicating for the past two decades.

The synthetic psychedelic landscape is chemically varied. Several compounds define it.

LSD remains the archetype. Active at 75–150 micrograms — doses measured not in milligrams but in micrograms, meaning a single gram could theoretically affect tens of thousands of people. Effects last 8–12 hours. Mechanism: primarily a serotonin receptor agonist, acting on the 5-HT2A receptor, the same receptor implicated in psilocybin, DMT, and mescaline. Current clinical research at Johns Hopkins and Imperial College London is examining its effects on depression, anxiety, and addiction.

MDMA sits in a different class — technically an entactogen, though the distinctions blur in practice. It triggers massive release of serotonin, dopamine, and norepinephrine, producing profound empathy, emotional openness, and a suppressed fear response. It is currently in Phase 3 clinical trials for PTSD. Results were striking enough that the FDA granted Breakthrough Therapy designation. The agency subsequently raised concerns about trial methodology, complicating the approval path — a development that reveals as much about the politics of psychedelic medicine as about the compound itself.

Ketamine is the only legally approved psychedelic-adjacent compound for depression in most Western countries, marketed as esketamine (Spravato) by Johnson & Johnson. It is a dissociative anesthetic, not a classical psychedelic — it acts on NMDA glutamate receptors rather than serotonin. It produces antidepressant effects within hours in patients who have failed multiple other treatments. Its clinical normalization has quietly shifted what mainstream psychiatry considers acceptable: altered states as therapeutic vehicles are no longer fringe.

DMT (dimethyltryptamine) occupies a peculiar borderland. It exists naturally in many plants and in trace amounts in mammalian brains. Synthetic DMT is chemically identical to the natural form. Smoked, it lasts 15–20 minutes and produces what subjects consistently describe as complete dissolution of ordinary reality — entity encounters, dimensional shifts, contact with presences that feel categorically real. The neuroscientist Rick Strassman ran the first government-approved human psychedelic research in the United States in twenty years at the University of New Mexico in the early 1990s, administering synthetic DMT intravenously to volunteers and documenting their experiences in detail. His book DMT: The Spirit Molecule remains one of the most carefully reported documents at the intersection of rigorous methodology and genuinely bewildering phenomenology.

2C-B (4-bromo-2,5-dimethoxyphenethylamine), one of Shulgin's compounds, runs shorter than LSD and shows strong dose-dependence — lower doses producing sensory enhancement, higher doses producing full psychedelic effects. Its gentler entry and exit profile has attracted therapeutic interest, though research is early.

This is the question that neuroimaging has started to answer — and the answer opens more than it closes.

The most significant finding involves the Default Mode Network (DMN): a set of interconnected brain regions active during mind-wandering, self-referencing, and the maintenance of continuous personal identity. The DMN is, in a meaningful sense, the neural substrate of the self as we ordinarily experience it. Under psychedelics, it breaks down. Its normally tight internal correlations dissolve. It becomes less dominant. Brain regions that do not ordinarily communicate with each other begin forming new, transient connections.

Robin Carhart-Harris and colleagues at Imperial College London have described this in terms of increased neural entropy — a measurable rise in brain complexity that correlates with the subjective experience of ego dissolution. The boundary between self and world becomes permeable, then disappears. This is not a metaphor. It has a neuroimaging signature.

Here is where it gets philosophically uncomfortable. That experience — the dissolution of the self, the sense of unity with something larger — is precisely what contemplative traditions across cultures have described as the pinnacle of practice. Tibetan Buddhist meditation masters, Sufi mystics, Christian contemplatives in the apophatic tradition: different languages, different cosmologies, identical phenomenological reports. Neuroimaging is beginning to show converging brain-state patterns in long-term meditators and psychedelic subjects.

This does not settle the deep question. It does not tell us whether the dissolution reveals something true about consciousness, or generates a useful fiction via unusual neurochemistry, or points toward something we have not yet developed the vocabulary to describe. But it rules out the dismissive reading. These are not confusion states. They are reproducible, measurable alterations in the architecture of conscious experience, with therapeutic effects that outlast the drug itself by months.

That last point demands attention. Most psychiatric medications require daily dosing to maintain effect. Psychedelics appear to produce lasting changes in mood, behavior, and psychological orientation from a small number of guided sessions. Patients with treatment-resistant depression. Smokers who had failed every cessation program. People dying of cancer with debilitating existential fear. Across multiple studies, one or two carefully guided psychedelic sessions produced improvements that conventional treatment had not touched — improvements that held at six-month follow-up. How a few hours of unusual neurochemistry can reorganize what years of therapy could not is one of the most genuinely interesting open questions in contemporary neuroscience.

The therapeutic renaissance is real. The suppression that preceded it was also real. Both facts need to be held at once.

Psychological destabilization is a documented risk, particularly for individuals with personal or family histories of psychosis or schizophrenia. The compounds themselves appear physiologically non-toxic at standard doses. The minds they act upon are not uniform. The intensity of these experiences can be genuinely overwhelming without adequate preparation, support, or screening. Clinical programs exclude participants with relevant histories for reasons that reflect real evidence, not pharmaceutical conservatism.

Set and setting — a principle Timothy Leary named and research has since thoroughly validated — determines trajectory more than dose alone. The same compound at the same dose can produce transformative insight in a structured therapeutic context and psychological crisis in an uncontrolled one. That is not an argument against these compounds. It is an argument for taking seriously the frameworks within which they are used.

The harder structural question concerns who gains access to what the research is building. Ketamine infusions cost hundreds to thousands of dollars per session out of pocket. MDMA-assisted therapy protocols, if approved, project multiple eight-hour sessions with two co-therapists present — an expensive model. The populations carrying the highest burdens of treatment-resistant trauma, depression, and addiction are often precisely those least able to afford premium therapeutic pricing. If the psychedelic renaissance delivers primarily to the affluent, that is not a therapeutic success. It is a replication of every other healthcare inequity under a more interesting mechanism.

This connects to a pattern of appropriation that has not been adequately examined. Ayahuasca, peyote, and psilocybin mushrooms — the natural precursors and structural inspirations for much synthetic psychedelic chemistry — have been used in sacred ceremonial contexts by indigenous peoples for millennia. Often while those same peoples faced active persecution. The current enthusiasm in Western research and therapeutic communities frequently takes the molecule and leaves the cosmology. That extraction carries no acknowledgment of the knowledge systems within which these substances were held and transmitted. The compounds did not arrive from nowhere. Neither did the frameworks that made their effects navigable.

People do not typically emerge from significant psychedelic experiences reporting an interesting neurological event. They report having understood something. Been shown something. Met something. They reach for the language of revelation — not because they are credulous, but because no other vocabulary fits what they encountered.

This creates an interpretive problem that neither science nor religion has cleanly resolved.

The reductionist reading: these are hallucinations. The brain, its ordinary filtering mechanisms temporarily dissolved, generates experiences that feel profound but are neurological noise — meaningful only in the way any intense emotional experience is meaningful. The mystical reading: these compounds remove the filters and reveal what is actually there — a reality more interconnected, more fundamentally unified than ordinary ego-bound perception allows.

Both readings may be partially correct. Both may miss the point.

What is difficult to explain away is the convergence. The entity encounters. The geometric visions. The sense of cosmic unity. The feeling of contact with something that seems to know you more fully than you know yourself. These appear with a regularity that cuts across culture, era, preparation level, and expectation. Subjects who have never read a word of mystical literature report experiences structurally identical to those described by Meister Eckhart, by Ramana Maharshi, by anonymous figures in the Tibetan tradition. The phenomenological content is not random. It is not obviously explained by cultural suggestion or wishful projection.

Rick Strassman sat with hundreds of DMT subjects in a clinical research setting in the early 1990s. He had a protocol. He had controls. He had scientific methodology. He was not prepared for how consistently people described encounters with presences, intelligences, beings — described not as hallucinations they were having, but as entities they were meeting. His willingness to report that honestly, without resolving it, is what makes DMT: The Spirit Molecule worth reading.

Hofmann understood this. He spent sixty years after Bicycle Day trying to articulate what he had seen — not the visual phenomena, but the epistemological fact underneath them. That ordinary human perception is not the full range of what perception can be. That the self we experience as continuous, bounded, and separate is a useful construction, not a metaphysical given. That the ordinary assumptions built into waking consciousness are assumptions, not facts.

He could not prove any of this. He also could not unfind it. That is precisely where the question lives.